MacroGenics, Inc. (MGNX)
- Motley Fool
Why MacroGenics Stock Is Skyrocketing Today
Shares of MacroGenics (NASDAQ: MGNX) were skyrocketing 27.8% higher as of 12:47 p.m. ET on Tuesday. A filing to the U.S. Securities and Exchange Commission on June 17 revealed that MacroGenics CFO James Karrels recently bought 40,000 shares. It's not unusual for clinical-stage biotech stocks to jump when key insiders buy shares.
- Simply Wall St.
James Karrels Is The Senior VP of MacroGenics, Inc. (NASDAQ:MGNX) And They Just Picked Up 26% More Shares
Whilst it may not be a huge deal, we thought it was good to see that the MacroGenics, Inc. ( NASDAQ:MGNX ) Senior VP...
- GlobeNewswire
MacroGenics to Participate in Upcoming Investor Conference
ROCKVILLE, MD, June 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference in June 2022: The JMP Securities Life Sciences Conference. MacroGenics’ management is scheduled to participate in a fireside chat on Thursday, June 16, 2022, at 12:00 pm ET, and w
